Option chain shows key data for CNBX Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for CNBX Pharmaceuticals.

CNBX Pharmaceuticals (OTC:CNBX) Stock, Option Chain

CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.

Cannabis

News

Penny Stocks

Markets

CNBX

CNBX Pharmaceuticals Inc. (OTCQB: CNBX) has acquired a controlling interest in TaGeza Biopharmaceuticals Ltd. The TaGeza research team remains committed to the company, and co-founder professor Benjamin Dekel (MD, PhD) will continue to serve as the company&#39;s chief scient

CNBX Acquires A Controlling Interest In Cancer Immunotherapy Developer

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) has changed its corporate name to &#34;CNBX Pharmaceuticals Inc.&#34;

Cannabics Pharmaceuticals Changes Name To CNBX Pharmaceuticals, Moves Ahead With Cancer Treatment Drug Research

Health Care

Small Cap

Success Stories

Press Releases

General

Cannabics Pharmaceuticals Announces Two New Provisional Patents: Compositions and Methods For Treating Cancer

CNBX PHARMACEUTICAL INC by CNBX Pharmaceuticals Inc.

Comments

CNBX Pharmaceuticals

CNBX Pharmaceuticals (CNBX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga